Abivax announces the release of its half-year financial report 2021

September 30, 2021 at 12:00 PM EDT

PARIS, France, September 30, 2021 – 6:00 pm (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2021 half-year financial report. This document is available in electronic version on the website of the company (www.abivax.com – “Investors”) and on the website of the French financial markets authority, AMF (www.amf-france.org).

About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

Contacts

Abivax                 
Communications
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63

Investors
LifeSci Advisors
Ligia Vela-Reid
lvela-reid@lifesciadvisors.com
+44 7413 825310

Press Relations & Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22

Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24

Public Relations France
DGM Conseil

Thomas Roborel de Climens
thomasdeclimens@dgm-conseil.fr
+33 6 14 50 15 84

Public Relations USA     
Rooney Partners LLC
Jeanene Timberlake
jtimberlake@rooneyco.com
+1 646 770 8858